Compare Cassava Sciences Inc (FLNA) vs Match Group Inc (MTCH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Match Group Inc — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Match Group Inc trades at $40.57 (market cap $9.36B). The key difference: Match Group Inc is far larger — about 176.1× Cassava Sciences Inc's market cap, and Match Group Inc pays a 1.99% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | MTCH | |
|---|---|---|
Market Cap | $53.14M | $9.36B |
Sector | Health | Media |
52-Week High | $4.64 | $40.11 |
52-Week Low | $1.09 | $28.90 |
Enterprise Value | -$33.43M | $12.31B |
Dividend Yield | — | 1.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
Match Group (MTCH) trades at $38.34, down 0.52% on the day, with a bullish technical signal supported by moving averages. The company maintains strong profitability with a 73.8% gross margin and 18.83% net income margin, though Q1 2026 earnings missed expectations. Recent news highlights Tinder's turnaround efforts and Hinge's growth, with upcoming Q2 2026 results on August 4, 2026.
The stock presents a moderate upside to the $41.63 consensus price target, supported by 53% analyst buy ratings. Key risks include Tinder's user decline and high debt levels, while positive cash flow trends and valuation discounts offer potential for patient investors amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →
